According to Gilead Sciences's latest financial reports the company's current revenue (TTM) is $27.11 B. In 2022 the company made a revenue of $27.28 B a decrease over the years 2021 revenue that were of $27.30 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $27.11 B | -0.61% |
2022 | $27.28 B | -0.09% |
2021 | $27.30 B | 10.6% |
2020 | $24.68 B | 9.98% |
2019 | $22.44 B | 1.46% |
2018 | $22.12 B | -15.24% |
2017 | $26.10 B | -14.09% |
2016 | $30.39 B | -6.89% |
2015 | $32.63 B | 31.13% |
2014 | $24.89 B | 122.2% |
2013 | $11.20 B | 15.45% |
2012 | $9.70 B | 15.71% |
2011 | $8.38 B | 5.48% |
2010 | $7.94 B | 13.38% |
2009 | $7.01 B | 31.4% |
2008 | $5.33 B | 26.14% |
2007 | $4.23 B | 39.78% |
2006 | $3.02 B | 49.19% |
2005 | $2.02 B | 53.13% |
2004 | $1.32 B | 52.63% |
2003 | $0.86 B | 85.92% |
2002 | $0.46 B | 99.68% |
2001 | $0.23 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 243.06% | ๐บ๐ธ USA |
Pfizer PFE | $58.49 B | 115.74% | ๐บ๐ธ USA |
AbbVie ABBV | $54.31 B | 100.32% | ๐บ๐ธ USA |
Eli Lilly LLY | $34.12 B | 25.85% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 3.96% | ๐บ๐ธ USA |
Biogen BIIB | $9.83 B | -63.73% | ๐บ๐ธ USA |
Illumina ILMN | $4.50 B | -83.39% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | $9.86 B | -63.60% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 121.70% | ๐บ๐ธ USA |